로딩 중…
지수 로딩 중…
팬젠
222110· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,885+3.94%
2026-06-19
Price Chart
팬젠-21.21%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 66.02B KRW |
| Revenue | 13.71B KRW |
| Net Income | 2.06B KRW |
| Total Assets | 33.46B KRW |
| Net Assets | 30.67B KRW |
| Employees | 75 |
| Value | |
| P/E | 31.97x |
| P/B | 2.15x |
| PEG | 16.40x |
| P/S | 4.82x |
| EV/EBITDA | 49.17x |
| FCF Yield | -0.56% |
| Profitability | |
| ROE | 6.73% |
| ROA | 6.17% |
| Op. Margin | 9.39% |
| Revenue Growth | 8.43% |
| Earnings Growth | 1.95% |
| Financial Health | |
| Debt Ratio | 9.07% |
| Total Debt | 1.00B KRW |
| FCF | -373.0M KRW |
| Cash | 3.70B KRW |
| Current Ratio | 8.67x |
| Net Debt/EBITDA | -2.10x |
| Performance | |
| 1Y Return | -21.21% |
| 1M Return | -14.00% |
| From 52W High | -42.60% |
| 1Y MDD | -38.56% |
| Trading | |
| Volume | 27,942 shares |
| Foreign Own. | 7.41% |
| Per Share | |
| EPS | 154 KRW |
| BPS | 2,273 KRW |
Company Info
PanGen, established in 2010 as a spin-off, was listed on KOSDAQ as a technology growth company in 2016. The company provides biosimilar EPO drug production and sales, biopharmaceutical contract manufacturing, and development technology transfer services, leveraging its PanGen CHO-TECH™ technology and GMP facilities. Its EPO drugs are sold in Asia and Saudi Arabia, and it has completed clinical Phase 3 sample production for Hemophilia A treatment, along with non-clinical trials for macular degeneration treatment and anti-cancer adjuvants. PanGen is headquartered in Suwon-si, Gyeonggi-do.